SPOTLIGHT -
EP. 1: Treatment After Progression on CDK 4/6i in mBC
EP. 2: SOLAR-1 Trial in Metastatic Breast Cancer
EP. 3: Payer Perspective of Coverage on Cancer Therapies
EP. 4: Payer Coverage on Repeat Biopsy in mBC
EP. 5: Advantages of Oral Taxanes in mBC
EP. 6: Compliance and Adherence to Therapy in mBC
EP. 7: Payer Coverage of IV Versus Oral Therapy in mBC
EP. 8: Evolving Treatment Landscape of R/R HER2+ mBC
EP. 9: HER2CLIMB and NALA Trials: R/R HER2+ mBC
EP. 10: SOPHIA Trial in R/R HER2+ mBC
EP. 11: Sequencing of Therapy in R/R HER2+ mBC
EP. 12: IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
EP. 13: Role of PARP Inhibition and I/O Therapy in TNBC
EP. 14: Treatment Options in Metastatic TNBC
EP. 15: Considerations for NGS Testing in mTNBC
EP. 16: Assessing the Value of Personalized Treatment in mBC
EP. 17: Closing Thoughts on Metastatic Breast Cancers
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
